从财务状况来看，百济神州在本季度实现了由亏损到盈利的转变。归属于母公司所有者的净利润有所改 善，去除非现金项目的影响后，经调整的营业利润为11.71亿元，而去年同期则是经调整营业亏损9.37亿 元。此外，报告期内经调整的净利润为8.85亿元，而上年同期则为净亏损10.82亿元。 综合来看，百济神州在2025年第一季度的业绩提升主要得益于产品销售收入的大幅增长以及公司在费用 管理方面的优化，这些措施显著提升了公司的经营效率。随着核心产品的持续增长和市场扩展，百济神 州在未来有望继续保持良好的发展态势。 百济神州（ONC.O）于5月7日发布了其2025年第一季度的主要财务数据。根据公告显示，公司在该季 度的营业总收入达到了80.48亿元，同比增长了50.2%。其中，产品销售收入为79.85亿元，同比上升了 49.9%。 在本季度中，百济神州自主研发的核心产品——百悦泽（泽布替尼）在全球市场的销售额达到了56.92 亿元，较去年同期增长了63.7%。具体而言，在美国市场，百悦泽的销售额为40.41亿元，同比增长了 61.9%；在欧洲市场，销售额达到8.36亿元，同比增长了75.4%；在中国市场，销售额为5.90亿元 ...

Q2 Holdings, Inc. QTWO reported upbeat earnings for the first quarter on Wednesday.The company posted quarterly earnings of 50 cents per share which beat the analyst consensus estimate of 47 cents per share. The company reported quarterly sales of $189.74 million which beat the analyst consensus estimate of $186.67 million.“We delivered strong results to start the year with solid performance across the business,” said Q2 Chairman and CEO Matt Flake. “Our first quarter bookings performance was marked by sign ...

丰田汽车2026年预估预计经营利润3.80万亿日元，预估4.69万亿日元。 预计净利润3.10万亿日元，预估4.07万亿日元。 预计销售净额48.50万亿日元，预估48.9万亿日元。 预计股息95.00日元，预估97.16日元。 ...

Core Insights - Amphastar Pharmaceuticals reported revenue of $170.53 million for the quarter ended March 2025, reflecting a year-over-year decline of 0.8% [1] - The earnings per share (EPS) for the same period was $0.74, down from $1.04 a year ago, with a surprise of +12.12% compared to the consensus estimate of $0.66 [1] - The reported revenue was a surprise of -0.69% against the Zacks Consensus Estimate of $171.71 million [1] Revenue Breakdown - Primatene MIST generated net revenues of $29.05 million, exceeding the average estimate of $27.64 million, representing a year-over-year increase of +20.2% [4] - Glucagon reported net revenues of $20.84 million, slightly above the estimated $20.24 million, but showed a year-over-year decline of -27% [4] - Lidocaine achieved net revenues of $13.64 million, surpassing the average estimate of $13.15 million, with a year-over-year increase of +6.8% [4] - Epinephrine's net revenues were $18.59 million, above the estimated $18.21 million, but reflected a significant year-over-year decline of -28.8% [4] Stock Performance - Amphastar's shares returned +0.5% over the past month, while the Zacks S&P 500 composite increased by +10.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

美股盘前，超微电脑跌约4%，公司再次下调全年销售预期，承认会遭受特朗普关税的冲击。AMD涨约 2%，公司一季度营收超预期，二季度营收指引也超预期。诺和诺德涨约6%，摩根大通分析师指出诺和 诺德下调今年业绩指引的决定已经反映在股价中。 ...

2025 年 05 月 06 日 公司点评 增持/下调 今世缘(603369) 目标价: 53.64 昨收盘:47.40 今世缘：2024 年稳健收官，2025 年顺利实现开门红 ◼ 走势比较 (40%) (28%) (16%) (4%) 8% 20% 24/5/6 24/7/16 24/9/25 24/12/5 25/2/14 25/4/26 ◼ 股票数据 | 总股本/流通(亿股) | 12.47/12.47 | | --- | --- | | 总市值/流通(亿元) | 590.98/590.98 | | 12 个月内最高/最低价 | 59.38/35.35 | | (元) | | 相关研究报告 <<今世缘：三季度业绩符合预期，产 品结构势能延续>>--2024-11-01 <<今世缘：业绩符合预期，后百亿时 代稳中有进>>--2024-08-19 <<今世缘：一季度开门红顺利收官， 开启后百亿征程>>--2024-05-05 多产品稳健增长，省内持续深耕省外快速渗透。分产品，2024 年公 司特 A+/特 A/A/B/C&D 分别实现营收 74.91/33.47/4.19/1.42/0.74 亿 元，同比 ...

31家北交所公司去年营收超10亿。 A股年报披露正式收官，北交所公司2024年的经营全貌随之出炉。 Wind统计显示，去年全年，北交所265家上市公司合计实现营业收入约1808.45亿元，平均每家营收6.82亿元。其 中，225家去年实现盈利，盈利面超过八成，逾百家去年增收又增利。 北证50成分股继续发挥业绩"压舱石"作用。2024年，50家指数样本公司合计实现营收713.39亿元，累计贡献了近 四成营收。 从单家公司情况看，北交所"一哥"贝特瑞（835185.BJ）居业绩榜首位，成为去年北交所唯一一家营收超百亿的公 司，当期营业收入142.37亿元、归母净利润9.3亿元，同比双双下滑。一诺威（834261.BJ）、同力股份 （834599.BJ）、颖泰生物（920819.BJ）等去年营收均超过50亿元。 现金分红也是今年年报季的"重头戏"。披露年报之际，北交所上市公司也纷纷打出"分红+转增"组合拳。同时，第 一财经从北交所方面了解到，2024年报披露期间，超九成盈利公司披露分红预案，叠加中期分红，2024年共计分 红金额59.68亿元，占上市公司净利润的43%。 | | | | 部分北交所上市公司2024年 ...

Interparfums (IPAR) reported $338.82 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 4.6%. EPS of $1.32 for the same period compares to $1.27 a year ago.The reported revenue represents a surprise of +0.47% over the Zacks Consensus Estimate of $337.22 million. With the consensus EPS estimate being $1.13, the EPS surprise was +16.81%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall St ...

Core Insights - Henry Schein reported $3.17 billion in revenue for Q1 2025, a slight year-over-year decline of 0.1% [1] - The EPS for the quarter was $1.15, up from $1.10 a year ago, indicating a positive trend in earnings [1] - The revenue fell short of the Zacks Consensus Estimate of $3.23 billion by 1.84%, while the EPS exceeded the consensus estimate of $1.11 by 3.60% [1] Revenue Performance - Geographic Revenue from International Dental Equipment was $197 million, below the average estimate of $209.20 million [4] - U.S. Distribution Revenue for Dental Equipment was $187 million, significantly lower than the estimated $232.79 million, reflecting a 25.4% decline year-over-year [4] - International Dental Merchandise revenue was $594 million, also below the estimate of $608.26 million [4] - U.S. Distribution Medical revenue was $1.03 billion, slightly above the estimate of $1.01 billion, showing a year-over-year increase of 1.6% [4] - International Dental revenue was $798 million, under the estimate of $824.47 million, with a year-over-year decline of 1.6% [4] - U.S. Distribution Dental Merchandise revenue was $591 million, exceeding the estimate of $569.68 million [4] - Global Specialty Products net sales were $367 million, slightly above the average estimate of $364.59 million [4] Stock Performance - Henry Schein's shares returned -0.3% over the past month, contrasting with the Zacks S&P 500 composite's +0.4% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

2025 年 5 月 5 日 公司研究 Q1 新事业部投产致利润承压，期待公司业绩逐步改善 ——迎丰股份（605055.SH）2024 年年报及 2025 年一季报点评 要点 24 年收入 /归母净利润同比+2.1%/+18.8%，25Q1 收入同比-5.5%，利润端亏损 迎丰股份发布 2024 年年报及 2025 年一季报。公司 2024 年实现营业收入 15.8 亿元，同比增长 2.1%，归母净利润 4418 万元，同比增长 18.8%，扣非归母净 利润 4363 万元，同比增长 42.6%，EPS 为 0.10 元，拟每股派发现金红利 0.06 元（含税）。 24 年公司归母净利率同比提升 0.4PCT 至 2.8%。分季度来看，24Q1~Q4 公司 单季度收入分别同比+7.0%/+5.3%/-3.0%/+0.2%，归母净利润分别同比减亏 52.7%/+68.1%/-93.2%/+36.6%。25Q1 公司实现收入 3.0 亿元，同比下滑 5.5%， 归母净利润-986 万元，利润端亏损主要系新事业部投产成本增加（即三迎丰工 厂）所致。 分业务来看，公司梭织/针织 24 年收入占比分别为 49.6%/4 ...